MIRA Pharmaceuticals (MIRA) Competitors $1.26 -0.14 (-9.96%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MIRA vs. ORMP, ADAG, IVVD, SLS, GNTA, RLMD, ANVS, PYRGF, PWUP, and EPRXShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Oramed Pharmaceuticals (ORMP), Adagene (ADAG), Invivyd (IVVD), SELLAS Life Sciences Group (SLS), Genenta Science (GNTA), Relmada Therapeutics (RLMD), Annovis Bio (ANVS), PyroGenesis Canada (PYRGF), PowerUp Acquisition (PWUP), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Oramed Pharmaceuticals Adagene Invivyd SELLAS Life Sciences Group Genenta Science Relmada Therapeutics Annovis Bio PyroGenesis Canada PowerUp Acquisition Eupraxia Pharmaceuticals MIRA Pharmaceuticals (NASDAQ:MIRA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Which has stronger earnings & valuation, MIRA or ORMP? Oramed Pharmaceuticals has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.56-2.26Oramed Pharmaceuticals$1.34M67.99$5.53M$0.514.43 Do institutionals & insiders hold more shares of MIRA or ORMP? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor MIRA or ORMP? Oramed Pharmaceuticals received 316 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 73.84% of users gave Oramed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesOramed PharmaceuticalsOutperform Votes31973.84% Underperform Votes11326.16% Which has more volatility & risk, MIRA or ORMP? MIRA Pharmaceuticals has a beta of 3.09, suggesting that its stock price is 209% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Does the media refer more to MIRA or ORMP? In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Oramed Pharmaceuticals and 0 mentions for MIRA Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.75 beat MIRA Pharmaceuticals' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment MIRA Pharmaceuticals Neutral Oramed Pharmaceuticals Positive Do analysts rate MIRA or ORMP? MIRA Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,006.72%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe MIRA Pharmaceuticals is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is MIRA or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -7.28% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Oramed Pharmaceuticals N/A -7.28%-6.22% SummaryOramed Pharmaceuticals beats MIRA Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.95M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E Ratio-2.2610.02126.5217.52Price / SalesN/A318.981,203.9085.12Price / CashN/A22.1633.3732.51Price / Book4.225.464.684.68Net Income-$11.98M$152.97M$118.36M$225.62M7 Day Performance-18.91%-4.33%-2.46%-2.04%1 Month Performance15.00%-8.65%-4.06%0.03%1 Year Performance-72.80%28.53%29.55%24.47% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals1.6575 of 5 stars$1.27-10.0%$14.00+1,006.7%-72.8%$23.18MN/A-2.262Positive NewsORMPOramed Pharmaceuticals1.478 of 5 stars$2.26-1.7%N/A+4.6%$92.72M$1.34M4.4310News CoverageADAGAdagene2.974 of 5 stars$2.09-5.9%$5.00+139.2%+52.6%$92.53M$815,746.000.00260News CoveragePositive NewsGap UpIVVDInvivyd2.5274 of 5 stars$0.77flat$7.52+878.6%-48.8%$91.88M$11.56M-0.39100Analyst ForecastSLSSELLAS Life Sciences Group1.424 of 5 stars$1.24-3.9%$3.00+141.9%+26.3%$90.79M$1M0.0016Gap UpGNTAGenenta Science2.3777 of 5 stars$4.70-4.9%$25.00+431.9%-13.8%$90.35MN/A0.007News CoverageRLMDRelmada Therapeutics4.0741 of 5 stars$2.85-4.4%$7.50+163.2%-3.4%$89.92MN/A0.0010ANVSAnnovis Bio1.8597 of 5 stars$6.51-2.5%$32.17+394.1%+8.1%$89.82MN/A-1.463PYRGFPyroGenesis CanadaN/A$0.49flatN/A+27.8%$89.52M$9.14M0.0090News CoverageGap UpPWUPPowerUp AcquisitionN/A$11.50flatN/AN/A$89.30MN/A0.00N/AEPRXEupraxia Pharmaceuticals2.4866 of 5 stars$3.62+11.0%$9.00+148.6%N/A$88.94MN/A0.0029Gap UpHigh Trading Volume Related Companies and Tools Related Companies Oramed Pharmaceuticals Competitors Adagene Competitors Invivyd Competitors SELLAS Life Sciences Group Competitors Genenta Science Competitors Relmada Therapeutics Competitors Annovis Bio Competitors PyroGenesis Canada Competitors PowerUp Acquisition Competitors Eupraxia Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRA Stock Alerts